By Jason Bock, Ph.D., CEO, and Duane Avant, CTO, CTMC
Manufacturing autologous cell therapies requires close coordination with clinical staff, as well as processes that scale out rather than scale up. To meet this demand, manufacturers and developers should, when and where feasible, engage early with manufacturers of digital systems to map out processes, identify and address operational bottlenecks, and ensure patients receive high-quality cell therapies in a timely manner.
read the full article here: Drug Discovery Online with Jason Bock & Duane Avant